7-2009-2347  |  New Marker for the Early Detection of Type I Diabetes

David Naor, HUJI, Faculty of Medicine, Molecular biology

Enables prediction of diabetes potency in high-risk individuals

Categories	Biomarkers, Diabetes
Development Stage	Proof of concept in mice
Patent Status	Provisional US  patent application filed
Market	The European diabetes diagnostics market earned revenues of U.S. $3.6 billion in 2008, estimated to reach $10.6 billion in 2015

Highlights

• New markers that can detect the asymptomatic early stage of type I diabetes (i.e. before increase in blood glucose levels) are essential because current markers are not sufficiently predictable.
• In these early stages a significant amount of pancreatic beta cells are still viable and may be recruited for disease treatment.
• Current markers for the early detection of type 1 diabetes can miss patients undergoing disease development.
• Principle demonstrated in diabetic animal models and a very limited number of samples from diabetic humans

Our Innovation

• New markers for early detection of type 1 diabetes to improve the prediction potency of type 1 diabetes development in high risk individuals.

Key Features

• Allows early initiation of treatment that could avert the need for insulin injections or allows reduction of frequency and dose of injections
• May be used independently or in combination with other early markers to improve reliability

Development Milestones

• Seeking funding for ongoing research and human trials to prove that use of the same method for predicting type 1 diabetes in mice can also be used in humans

The Opportunity

• Up to 1,000,000 people in the U.S. are estimated to have type 1 diabetes, with about 30,000 new cases diagnosed each year
• An estimated 285 million people worldwide are affected by diabetes, expected to reach 438 million by 2030; approximately 10% of people with diabetes have type 1 diabetes and the incidence of type 1 diabetes is rising globally.

 

Contact for more information:
Ariela Markel , VP Licensing, Biotechnology, +972-2-6586608

BACK